Cite
MLA Citation
Mathias Rummel et al.. “Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.” Lancet oncology, vol. 17, no. 1, n.d., pp. 57–66. http://access.bl.uk/ark:/81055/vdc_100029937011.0x00002a